Hematology

Rheumatoid Arthritis

Questions discussed in this category

In a patient with a Factor V Leiden heterozygous mutation but no prior thrombosis, would you consider using a JAK inhibitor for the treatment of spondyloarthritis or rheumatoid arthritis if other options have been ineffective?

1 Answer available

How would you approach treating patients with RA refractory to cDMARDs and a prior history of MALT lymphoma?

1 Answer available

How do you counsel patients on JAK inhibitors about the risk of venous thromboembolism, MACE, and cancer?

1 Answer available

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?

2 Answers available

Papers discussed in this category

JAMA network open, 2018-11-02

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.

RMD open, 2022 Nov

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.

Related Topics in Hematology